Vimpat (lacosamide) is a Schedule V controlled substance because it produced measurable euphoria and drug-liking effects in clinical studies, meaning it carries some potential for abuse. Schedule V is the lowest level of control under federal law, reflecting the fact that this risk is small compared to most other controlled medications. Still, the designation affects how your prescription is handled at the pharmacy.
What Abuse Potential Studies Found
Before Vimpat was approved in 2008, the FDA required human abuse potential testing. In a study of people with a history of abusing central nervous system drugs, doses of 200 to 800 mg of lacosamide produced drug-liking scores on standardized scales that were clearly different from placebo. At the highest dose (800 mg, well above the normal therapeutic range), those scores looked similar to alprazolam, a Schedule IV benzodiazepine.
Separate Phase 1 trials in healthy volunteers turned up reports of euphoria, and a notably high rate of participants described “feeling drunk.” In animal studies, lacosamide was self-administered at rates higher than saline, and its effects partially mimicked those of both alprazolam and phenobarbital. These behavioral signals were consistent across species: lacosamide can produce the kinds of pleasant or intoxicating sensations that make a drug attractive for misuse.
The critical detail, though, is that these effects were transient. They didn’t last as long as the effects of alprazolam, and they occurred primarily at doses higher than what’s prescribed for epilepsy. That’s why Vimpat landed in Schedule V rather than Schedule IV or higher.
How the DEA Made the Decision
The DEA’s final rule, published in May 2009, evaluated lacosamide against three criteria required by the Controlled Substances Act. First, the agency determined that lacosamide has a low potential for abuse relative to Schedule IV drugs. Second, it has a currently accepted medical use in the United States (treating partial-onset seizures). Third, abuse of lacosamide may lead to limited physical or psychological dependence compared to Schedule IV substances.
Interestingly, the FDA’s own advisory committee initially recommended Schedule IV placement, the same tier as alprazolam and phenobarbital. The DEA ultimately placed it one step lower, in Schedule V, because the abuse signals were weaker and shorter-lived than those benchmark drugs. Schedule V is the same tier as cough preparations containing small amounts of codeine.
How Vimpat Works in the Brain
Vimpat controls seizures through a mechanism unlike any other epilepsy drug on the market. Most sodium channel-blocking seizure medications work by interacting with what’s called the “fast inactivation” state of sodium channels in nerve cells, essentially hitting the brakes on neurons that are firing too rapidly over very short time windows (milliseconds). Lacosamide doesn’t touch fast inactivation at all.
Instead, it enhances “slow inactivation,” a process that operates on a scale of seconds rather than milliseconds. When neurons fire repeatedly over several seconds, lacosamide shifts those sodium channels into a resting state more readily, making it harder for a seizure to build and sustain itself. This unique mechanism is what makes Vimpat effective for seizures, but the fact that it’s active in the central nervous system and affects how nerve cells fire also explains why it can produce sedation and euphoria at higher doses.
How Most Seizure Drugs Compare
The majority of commonly prescribed epilepsy medications are not controlled substances. Drugs like levetiracetam, lamotrigine, carbamazepine, valproic acid, and topiramate can all be prescribed and refilled without the restrictions that come with scheduling. Vimpat is an outlier in this regard. The other major class of seizure medications that carry controlled status are benzodiazepines like clonazepam and clorazepate, which sit in Schedule IV due to their higher abuse and dependence risk. Gabapentin and pregabalin, which are also used for seizures, are Schedule V at the federal level as well.
What This Means for Your Prescription
As a Schedule V drug, Vimpat comes with a few practical restrictions that don’t apply to non-controlled seizure medications, though they’re less burdensome than those for higher-schedule drugs.
- Refills: Your prescription can be refilled up to five times within six months of the date it was written. After that, you’ll need a new prescription from your provider.
- Pharmacy transfers: If you need to move your prescription to a different pharmacy, the transfer must happen directly between two licensed pharmacists. It’s generally limited to a one-time transfer, unless both pharmacies share the same electronic database, in which case multiple transfers are allowed up to the maximum refills your prescriber authorized.
- Partial fills: If your pharmacy doesn’t have enough tablets to fill the full prescription, they can give you a partial fill, but no dispensing can occur after six months from the original prescription date.
State laws can add further restrictions on top of these federal rules. Some states treat Schedule V drugs more strictly than federal law requires, so your experience at the pharmacy may vary depending on where you live. In everyday practice, though, most people taking Vimpat for epilepsy find that the controlled substance requirements add only minor inconvenience, mainly the need for a new prescription every six months rather than open-ended refills.